Skip to content
The U.S. will soon have enough monkeypox vaccine available “for everyone in the at-risk community to receive two doses of vaccine,” said White House […]
White House: U.S. will soon have enough monkeypox vaccine for everyone at risk Read More »
The U.S. maternal mortality rate was 23.8 deaths per 100,000 live births as of 2020, an increase from 20.1 in 2019. And the maternal
Dobbs v. Jackson likely to increase maternal mortality – especially among Black mothers Read More »
Researchers are harnessing genetics to better understand the significant threat and dangers of drug-resistant tuberculosis (TB). However, we need policies that stimulate R&D. According
Researchers seek ways to tackle drug-resistant tuberculosis Read More »
The US Food and Drug Administration (FDA) is “close to authorizing updated doses that would target the versions of the virus now circulating,” Dr.
Biden administration to offer updated jabs in fall booster campaign Read More »
The U.S. Food and Drug Administration (FDA) has received Moderna’s application for emergency use authorization for its bivalent booster vaccine, mRNA-1273.222, which targets the
Moderna’s bivalent booster awaits emergency use authorization Read More »
Updated efficacy data from a Phase 2/3 trial testing three 3-g doses of the Pfizer-BioNTech COVID-19 vaccine in children aged 6 months to 4
Pfizer: COVID-19 vaccine effective in children 6 months to 4 years Read More »
Biotech partners Pfizer and BioNTech announced on Monday that they have requested Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA)
Pfizer-BioNTech requests federal authorization for Omicron-adapted booster Read More »
The practice of making drug makers give rebates to payers encourages Medicare Part D insurers to steer patients away from generic drugs that cost
HHS probe: Insurer PBMs pocket rebates as patients, taxpayers pay more Read More »
Despite the advancement of prevention, detection, and early treatment options for many cervical cancers, late-stage cervical cancer diagnoses are up in the United States,
Late-stage cervical cancer on the rise despite jab, early treatment options Read More »
The European Commission (EC) has granted Marketing Authorization for the first twice-yearly HIV therapy, Sunlenca (lenacapavir), developed by Gilead Sciences, the biopharmaceutical company announced
Sunlenca, the first twice-yearly HIV therapy, approved by European Commission Read More »
